Literature DB >> 10684580

AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia.

K Barton1, G Nucifora.   

Abstract

Hematopoiesis is the complex developmental process through which undifferentiated, pluripotent, hematopoietic stem cells come to generate mature, functional blood cells. This process is regulated in large part by specific transcription factors that control expression of genes necessary for the developmental sequence. Leukemias represent one form of disruption of this normal developmental process, and studies over the past few years have shown that many of the genes that underlay leukemogenesis are also essential for normal hematopoiesis. In an interesting recent example, Song et al.((1)) demonstrate that haploinsufficiency of the AML1 gene is the genetic basis of a form of familial thrombocytopenia which predisposes the affected individuals to the development of acute myeloid leukemia. Here we summarize Song's paper and current information describing the interesting dosage effects of this gene and other members of its gene family. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684580     DOI: 10.1002/(SICI)1521-1878(200003)22:3<214::AID-BIES2>3.0.CO;2-I

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  3 in total

1.  Mapping of complex regulatory elements by pufferfish/zebrafish transgenesis.

Authors:  E V Rothenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

Review 2.  Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus.

Authors:  Marta E Alarcón-Riquelme
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

3.  The transcription factor Ets1 is important for CD4 repression and Runx3 up-regulation during CD8 T cell differentiation in the thymus.

Authors:  Monica Zamisch; Linhua Tian; Roland Grenningloh; Yumei Xiong; Kathryn F Wildt; Marc Ehlers; I-Cheng Ho; Rémy Bosselut
Journal:  J Exp Med       Date:  2009-11-16       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.